Blood-Nanoparticle Interactions Create a Brain Delivery Superhighway for Doxorubicin
Zhuoxuan Li,Tatyana Kovshova,Julia Malinovskaya,Julian Knoll,Saeed Shanehsazzadeh,Nadezhda Osipova,Anastasia Chernysheva,Pavel Melnikov,Svetlana Gelperina,Matthias Wacker
DOI: https://doi.org/10.2147/ijn.s440598
IF: 7.033
2024-03-05
International Journal of Nanomedicine
Abstract:Zhuoxuan Li, 1 Tatyana Kovshova, 2 Julia Malinovskaya, 2 Julian Knoll, 1 Saeed Shanehsazzadeh, 1 Nadezhda Osipova, 2 Anastasia Chernysheva, 3 Pavel Melnikov, 2 Svetlana Gelperina, 2 Matthias G Wacker 1 1 National University of Singapore, Department of Pharmacy and Pharmaceutical Sciences, Faculty of Science, Singapore; 2 Dmitry Mendeleev University of Chemical Technology of Russia, Moscow, Russia; 3 V. Serbsky Federal Medical Research Centre of Psychiatry and Narcology of the Ministry of Health of the Russian Federation, Moscow, Russia Correspondence: Matthias G Wacker, Email Purpose: This study investigated the brain targeting mechanism of doxorubicin-loaded polybutyl cyanoacrylate (PBCA) nanoparticles, particularly their interactions with the blood-brain barrier (BBB). The BBB protects the brain from drugs in the bloodstream and represents a crucial obstacle in the treatment of brain cancer. Methods: An advanced computer model analyzed the brain delivery of two distinct formulations, Doxil ® and surfactant-coated PBCA nanoparticles. Computational learning was combined with in vitro release and cell interaction studies to comprehend the underlying brain delivery pathways. Results: Our analysis yielded a surprising discovery regarding the brain delivery mechanism of PBCA nanoparticles. While Doxil ® exhibited the expected behavior, accumulating in the brain through extravasation in tumor tissue, PBCA nanoparticles employed a unique and previously uncharacterized mechanism. They underwent cell hitchhiking, resulting in a remarkable more than 1000-fold increase in brain permeation rate compared to Doxil ® (2.59 × 10 − 4 vs 0.32 h − 1 ). Conclusion: The nonspecific binding to blood cells facilitated and intensified interactions of surfactant-coated PBCA nanoparticles with the vascular endothelium, leading to enhanced transcytosis. Consequently, the significant increase in circulation time in the bloodstream, coupled with improved receptor interactions, contributes to this remarkable uptake of doxorubicin into the brain. Keywords: BBB, brain targeting, CNS, modeling, doxorubicin, drug delivery Graphical Brain cancers include several primary and secondary tumors such as glioblastoma multiforme and brain metastases. Glioblastoma multiforme is one of the most aggressive cancers worldwide; it comes with an average survival of 12–15 months after diagnosis and a two-year survival rate of 25%. 1 Even more concerning, brain metastases from lung and breast cancers affect up to 200,000 patients per year. 2 Once a tumor spreads into the brain, the median survival under first-line treatment is 9.2 months only. 2 The blood-brain barrier (BBB) still poses a challenge in the treatment of brain cancer. It is created by the vascular endothelial cells in the brain that form tight junctions and inhibit the paracellular transport from blood circulation into the central nervous system (CNS). To date, most anticancer drugs cannot be delivered to the brain in sufficient quantity. 3–5 Nanomedicines such as liposomes and coated nanoparticles have been developed as a feasible strategy to deliver those therapeutical moieties to their target sites 4,6–8 (Figure 1A). Transporters can facilitate the selective uptake of therapeutical agents from the blood vessel into the brain. They include ion channels, carrier molecules, and receptor-initiated delivery through the formation of vesicles followed by transcytosis (Figure 1Bi). Figure 1 Possible ways for nanomedicines accessing to lesion locations in the brain. ( A ) Illustration of the mechanism of blood cell hitchhiking facilitated by surfactant-coated nanoparticles. Liposomes bind to blood cells to a much lower extent and do not utilize an active uptake mechanism. ( B ) Entry routes into the brain using (i) direct transporter-mediated transcytosis through interaction with the BBB, (ii) extravasation at the tumor site, and (iii) cell shuttling which facilitates receptor-mediated transcytosis. Cell hitchhiking increases the distribution of the drug into the brain significantly. Created with BioRender.com. Tumor growth together with neuroinflammation often leads to a local breakdown of the BBB that allows larger molecules and nanoparticles to enter the tumor site (Figure 1Bii). 4,6–9 As a consequence, nanoparticles, and liposomes have been developed that deliver their payload to malignant tissues in the brain. Although this localized uptake comes with higher selectivity for the tumor area, the invasive grow -Abstract Truncated-
pharmacology & pharmacy,nanoscience & nanotechnology